The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://francestlvn963003.wikibuysell.com/2049434/glp_3_retatrutide_a_comparative_analysis